Regeneron Pharmaceuticals, Inc. (REGN)

Nasdaq: REGN · Pharmaceutical Preparations · Tarrytown, NY · filing with the SEC since 1995

Grade7.3

◀ Past 7.9● Present 8.5▶ Future 5.0

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts in millions. The fiscal year ends in December.

Income statement, by fiscal year, newest first
Fiscal year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Report filed	Feb 4, 2026	Feb 5, 2025	Feb 5, 2024	Feb 6, 2023	Feb 7, 2022	Feb 8, 2021	Feb 7, 2020	Feb 7, 2019	Feb 8, 2018	Feb 9, 2017
Revenue	14,342,900	14,202,000	13,117,200	12,172,900	16,071,700	8,497,100	6,557,600^r	5,145,600^r	5,872,200	4,860,400
Cost of revenue	·	·	·	·	·	·	402,800	237,500	202,507	194,624
Research and development	5,850,200	5,132,000	4,439,000	3,592,500	2,860,100^r	2,647,000^r	2,450,000^r	1,468,800^r	2,075,100^r	2,052,300^r
Selling, general and administrative	2,700,000	2,954,400	2,631,300	2,115,900	1,824,900	1,346,000	1,341,900^r	1,127,200^r	1,320,400^r	1,177,700^r
Total costs and expenses	10,765,000	10,211,300	9,070,100	7,434,000	7,124,900	4,920,500	4,347,800^r	2,611,200^r	3,792,600^r	3,529,700^r
Operating income	3,577,900	3,990,700	4,047,100	4,738,900	8,946,800	3,576,600	2,209,800	2,534,400	2,079,600^r	1,330,700^r
Interest expense	43,800	55,200	73,000	59,400	57,300	56,900	30,200	28,200	25,100	7,200
Interest income (expense), net	·	·	·	·	·	·	·	·	-25,119	-7,195
Other income (expense), net	1,696,600	844,400	225,200	179,300	436,300	290,700	249,500	47,300	24,000^r	6,300^r
Total non-operating income (expense)	1,652,800	789,200	152,200	119,900	379,000	233,800	219,300	19,100	-1,100^r	-900^r
Income before income taxes	5,230,700	4,779,900	4,199,300	4,858,800	9,325,800	3,810,400	2,429,100	2,553,500	2,078,500^r	1,329,800^r
Income tax expense	725,800	367,300	245,700	520,400	1,250,500	297,200	313,300	109,100	880,000	434,300^r
Net income	4,504,900	4,412,600	3,953,600	4,338,400	8,075,300	3,513,200	2,115,800	2,444,400	1,198,500^r	895,500^r
Earnings per share, basic	43.07	40.90	37.05	40.51	76.40	32.65	19.38	22.65	11.27	8.55
Earnings per share, diluted	41.48	38.34	34.77	38.22	71.97	30.52	18.46	21.29	10.34	7.70
Weighted average shares, basic	104.6	107.9	106.7	107.1	105.7	107.6	109.2	107.9	106.3^r	104.7^r
Weighted average shares, diluted	108.6	115.1	113.7	113.5	112.2	115.1	114.6	114.8	115.9^r	116.3^r

As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. ^r restated by the company in a later report; ^b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.

What each line is, and the XBRL concept behind it

Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax

Cost of revenue what it cost to make or buy what it sold

us-gaap:CostOfGoodsAndServicesSold
us-gaap:CostOfGoodsSold

Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense

Selling, general and administrative the cost of selling and of running the companyus-gaap:SellingGeneralAndAdministrativeExpense

Total costs and expenses every operating cost, the cost of revenue includedus-gaap:CostsAndExpenses

Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss

Interest expense what its borrowing cost

us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpense

Interest income (expense), net interest earned less interest paid, outside the businessus-gaap:InterestIncomeExpenseNonoperatingNet

Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense

Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense

Income before income taxes profit before tax

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit

Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss

Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic

Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted

Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic

Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

SI Assistanton REGN · research, not advice